Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Martek Biosciences---- future biotech cash cow! -- Ignore unavailable to you. Want to Upgrade?

To: Saulamanca who wrote (200)	1/12/2002 4:20:34 PM
From: Saulamanca	Read Replies (1) \| Respond to of 258

New Enfamil LIPIL enfamil.com Bristol-Myers Squibb press release New Enfamil Lipil™ Is The First And Only Infant Formula To Contain Additional Nutrients Important To Babies' Mental And Visual Development bms.com

To: Saulamanca who wrote (200)	1/15/2002 5:06:53 AM
From: Asymmetric	Read Replies (1) \| Respond to of 258

Jim, MATK got it's lift on Monday. Up another 5.4% (+1.5). With trading volume WAY above average, momentum says this stock is going higher and that institutions are getting into stock. As you know it often takes institutions many days, if not weeks, to accumulate their positions...especially in a stock that once saw an average daily trading volume of 80,000 shares. However, manufacturing capacity constraints and relatively low yields at present will put restraint on stock as far as fundamental valuation. However, with Wall Street desperately grasping for good growth stories, that may not matter, as analysts shift investor focus to potential future markets beyond infant formula to justify continued run-up in price... along with the fact that many institutions and funds are just learning about this company. Congrats. Peter